

The long-chain monounsaturated cetoleic acid improves the efficiency of the *n*-3 fatty acid metabolic pathway in Atlantic salmon and human HepG2 cells

Tone-Kari Knutsdatter Østbye*, Gerd Marit Berge, Astrid Nilsson, Odd Helge Romarheim, Marta Bou and Bente Ruyter

Nofima, NO-1431 Ås, Norway

(Submitted 7 January 2019 – Final revision received 20 May 2019 – Accepted 11 June 2019; First published online 3 July 2019)

Abstract

The present study aimed to determine if the long-chain MUFA cetoleic acid (22 : 1*n*-11) can improve the capacity to synthesise the health-promoting *n*-3 fatty acids EPA and DHA in human and fish models. Human hepatocytes (HepG2) and salmon primary hepatocytes were first enriched with cetoleic acid, and thereafter their capacities to convert radio-labelled 18 : 3*n*-3 (α -linolenic acid, ALA) to EPA and DHA were measured. Increased endogenous levels of cetoleic acid led to increased production of radio-labelled EPA + DHA in HepG2 by 40 % and EPA in salmon hepatocytes by 12 %. In order to verify if dietary intake of a fish oil rich in cetoleic acid would have the same beneficial effects on the *n*-3 fatty acid metabolic pathway *in vivo* as found *in vitro*, Atlantic salmon were fed four diets supplemented with either sardine oil low in cetoleic acid or herring oil high in cetoleic acid at two inclusion levels (Low or High). The diets were balanced for EPA + DHA content within the Low and within the High groups. The salmon were fed these diets from 110 to 242 g. The level of EPA + DHA in liver and whole-body retention of docosapentaenoic acid and EPA + DHA relative to what was eaten, increased with increased dietary cetoleic acid levels. Thus, it is concluded that cetoleic acid stimulated the synthesis of EPA and DHA from ALA in human HepG2 and of EPA in salmon hepatocytes *in vitro* and increased whole-body retention of EPA + DHA in salmon by 15 % points after dietary intake of cetoleic acid.

Key words: EPA: DHA: α -Linolenic acid: Atlantic salmon: Liver: Cell culture: Hepatocytes

Fatty fish species are in general good sources of the healthy *n*-3 fatty acids EPA (20 : 5*n*-3) and DHA (22 : 6*n*-3) for human consumption. However, there are differences in fatty acid compositions between pelagic fish species. While the North Atlantic fishes capelin and herring contain lower levels of EPA and DHA than the South American sardine, approximately 8 % compared with approximately 23 % of total fatty acids, respectively⁽¹⁾, they are richer in long-chain (LC) MUFA, in particular cetoleic acid (22 : 1*n*-11) with approximately 17–22 % compared with approximately 1 % in sardine⁽¹⁾. EPA and DHA are essential nutrients well known for their beneficial health effects both in salmon and humans^(2–4). Compared with EPA and DHA, relatively little is known about the physiological functions and health impact of different MUFA found in fish oils. Some early studies reported that fish oils rich in MUFA may have beneficial effects on CHD in humans⁽⁵⁾. The MUFA were assumed to increase the peroxisomal β -oxidation and thereby improve the synthesis of the health-promoting long-chain *n*-3 fatty acids. Other health benefits of MUFA reported are hypolipidemic and anti-inflammatory effects^(6,7). Recently, fish oils rich in MUFA were shown

to attenuate atherosclerosis in mouse models⁽⁸⁾. There are however very limited number of studies comparing the effects of different fish oils with the same levels of EPA and DHA and only differing in MUFA, which is required to be able to understand the specific MUFA effects. More studies are therefore required in order to elucidate the potential health impact of specific MUFA as for instance cetoleic acid.

It is known that dietary cetoleic acid is highly utilised as an energy source in salmon and trout^(9,10). Less is known for mammals, but the finding in rats that 22 : 1 fatty acids can first go through chain shortening by peroxisomal β -oxidation to 20 : 1, and then further to 18 : 1 and 16 : 1 through mitochondrial β -oxidation, indicates that this fatty acid could also be utilised as an energy source in mammals⁽¹¹⁾. LC-MUFA are also found to increase the peroxisomal β -oxidation capacity in rats⁽¹²⁾. Peroxisomal β -oxidation is also responsible for converting 24 : 6*n*-3 to DHA, the last step in the synthesis of DHA⁽¹³⁾ and this makes it interesting to study if cetoleic acid influences the capacity in both mammalian and fish species to convert α -linolenic acid (ALA; 18 : 3*n*-3) to EPA and DHA through the potential stimulation of peroxisomal β -oxidation. Studies have

Abbreviations: ALA, α -linolenic acid; BSA, bovine serum albumin; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; FCR, feed conversion ratio; HIS, hepatosomatic index; LC, long-chain.

* **Corresponding author:** T.-K. K. Østbye, fax +47 77 62 91 00, email tone-kari.ostbye@nofima.no

shown that the synthesis of EPA and DHA in Atlantic salmon can be stimulated to a certain degree by bioactive fatty acids from plants like petroselinic acid that stimulates peroxisomal β -oxidation⁽¹⁴⁾. The high content of the MUFA petroselinic acid (18 : 1*n*-12) in coriander oil as supplement in the diet to rainbow trout increased cellular production of DHA in hepatocytes possibly due to increased peroxisomal β -oxidation⁽¹⁴⁾. Neither Atlantic salmon nor humans can produce EPA and DHA by *de novo* synthesis. Both species are dependent on the essential fatty acid ALA, which is the precursor for EPA and DHA. The efficiency of the conversion of ALA to EPA and DHA is quite low in both species but can be improved by different factors. Both diet compositions, life stage, genotype, and growth influence the capacity for EPA and DHA synthesis in salmon^(15–20). In humans, it is shown that males and females have differences in the conversion capacities⁽²¹⁾. In females, the conversion capacity of ALA to DHA was <10 %, whereas the capacity in males was <3 %^(21,22). Interestingly in pregnant women, the plasma phosphatidylcholine-DHA concentration was increased between weeks 16 and 40 of gestation, possibly to facilitate DHA supply to the offspring⁽²³⁾.

EPA and DHA are synthesised through multiple steps from ALA, in a pathway that is relatively well conserved between different species⁽¹³⁾, with similar enzymes responsible for the different steps in humans (reviewed by Zhang *et al.*⁽²⁴⁾) and salmon^(25,26). The pathway consists of several elongation and desaturation steps, in addition to a chain-shortening peroxisomal β -oxidation step producing DHA. Dietary fatty acids may exert a great influence on the efficiency of the pathway. High dietary levels of DHA inhibit, by feedback inhibition, the *n*-3 metabolic pathway both in humans and in Atlantic salmon^(27–29), whereas lack of DHA in the diet stimulates the *n*-3 fatty acid biosynthetic pathway in salmon^(3,4,30). The DHA status in humans on vegetarian or vegan diets has been shown to be lower than those on omnivore diets (reviewed by Burdge *et al.*⁽³¹⁾), but there appears to be no evidence of increased DHA biosynthesis in these groups⁽³²⁾. This is in contradiction to what is found in Atlantic salmon, where deficiency in EPA and DHA leads to a significant increase in their innate capacities for EPA and DHA production from ALA^(3,30).

Because linoleic acid (18 : 2*n*-6) competes with ALA for the enzymes of the biosynthetic pathway of EPA and DHA, the linoleic acid content in the diet, which is in particular high in human diets, can influence the conversion of ALA to EPA and DHA. Dietary intake of ALA, on the other hand, has in several human studies been reported to increase EPA content in plasma phospholipid, but not increased DHA⁽³³⁾. In Atlantic salmon studies, moderate dietary ALA levels have also been shown to increase EPA production⁽³⁰⁾.

Aquaculture production worldwide is expected to increase in the coming years, and at the same time, the availability of fish oil on the world market is stable but limited. This leads to a lack of the valuable *n*-3 fatty acids for fish feed production by the aquaculture industry, but possibly also for the production of *n*-3 products for human consumption by the nutraceutical industry if the world human population grows as expected⁽³⁴⁾. It is therefore of high importance to develop strategies to improve utilisation of existing fish oils by improving different species innate capacities for EPA and DHA production from ALA.

In the present study, the effect of cetoleic acid on the capacities for EPA and DHA synthesis from ALA was studied

in vitro in human and salmon hepatocytes and *in vivo* in Atlantic salmon after dietary intake of fish oil rich in this fatty acid. Improved synthesis of EPA and DHA may have positive health effects in both humans and salmon.

Materials and methods

Materials

Atlantic salmon (*Salmo salar*, 200 g) for the *in vitro* study were obtained from NIVA. HepG2 cells (derived from the liver tissue of a patient with hepatocellular carcinoma) were purchased from American Type Culture Collection. NaCl, KCl, HEPES, EDTA, CaCl₂, L-15, fetal bovine serum (FBS), sodium bicarbonate, penicillin–streptomycin solution (100×), Trypan blue, bovine serum albumin (BSA), PBS, Tris, peroxidase, FAD, NaOH, 2',7'-dichlorofluorescein diacetate (reduced form), palmitoyl coenzyme A lithium salt (PalmCoA) and 18 : 3*n*-3 were purchased from Sigma-Aldrich. L-15 Glutamax was obtained from Invitrogen, metacain from Norsk Medisinaldepot, laminin and chloroform from Merck Millipore, collagenase from Worthington, ¹⁴C-18 : 3*n*-3 from American Radiolabel Chemicals Inc., RNeasy Plus Mini Kit from Qiagen, Dulbecco's modified Eagle's medium (DMEM), PureLink Pro 96 RNA Purification Kit, PureLink Dnase set and primers from Thermo Fisher Scientific, SYBR Green I Master mix and LightCycler®480 from Roche Applied Science, TaqMan® Reverse Transcription Reagents from Applied Biosystems, cetoleic acid (22 : 1*n*-11) from BOC Sciences and lactate dehydrogenase assay from Abcam. Ecoscint A scintillation liquid was purchased from National Diagnostics Inc. The scintillation counter TRI-CARB 1900 TR was obtained from Packard Instrument Co.

Ethics statement

The feeding trial was performed at Nofima Sunndalsøra Research Station, which is approved by the Norwegian Animal Research Authority (NARA). Slaughtering and sampling of fish for both *in vivo* and *in vitro* trials were performed in accordance with the Norwegian Animal Welfare act. No NARA approval was required for the feeding trial according to Dr G. Bæverfjord (Nofima), appointed by NARA.

Isolation and culturing of salmon hepatocytes

Hepatocytes were isolated according to the method of Dannevig & Berg⁽³⁵⁾. The fish were anaesthetised in Metacain, the abdominal cavity exposed, and the vena porta cannulated. The liver was perfused with an EDTA buffer (0.14 M NaCl, 0.01 M KCl, 0.01 M HEPES, 0.02 M EDTA disodium salt, pH 7.4) to remove Ca and thereafter with a perfusion buffer containing collagenase (0.14 M NaCl, 0.01 M KCl, 0.01 M HEPES, 740 000 U/l collagenase, 0.001 M CaCl₂, pH 7.4) to digest the tissue. The hepatocytes were subsequently isolated by gentle shaking of the digested liver in L-15 medium, filtered through a 100- μ m nylon filter and washed three times in L-15 medium. The hepatocytes were resuspended in L-15 Glutamax culture medium containing 10 % FBS, 9 mM sodium bicarbonate, 1 % penicillin–streptomycin solution and 5 mM HEPES. Cell viability was assessed by staining with Trypan blue (0.4 %). Approximately 10⁷ hepatocytes were plated onto 25 cm² cell flasks precoated with laminin for the following



analysis: capacity for conversion of ALA to EPA and DHA (four replicates), fatty acid composition (three replicates) and acyl-CoA oxidase enzyme activity (three replicates). Doses of 18 : 3*n*-3 and cetoleic acid are within physiological levels, and incubation time was selected based on experience from previous studies⁽³⁶⁾. The cells were incubated for 3 h at 13°C prior to the addition of experimental medium containing 0, 20, 40, 60 or 80 μM cetoleic acid in L-15 Glutamax with 2% FBS, 9 mM sodium bicarbonate, 1% penicillin–streptomycin solution and 5 mM HEPES. The cells were cultured for 20 h and then added fresh experimental medium, in addition to ¹⁴C-18 : 3*n*-3 (final concentration of 7 μM) in cells designated for analysis of conversion capacity or non-radio-labelled in cells for the other analyses. The fatty acids 18 : 3*n*-3, ¹⁴C-18 : 3*n*-3 and cetoleic acid were added as a sodium salt bound to BSA (in the ratio 1:2:7). The cells were incubated for 48 h, and then washed twice in 1% BSA and twice in PBS before harvesting in PBS for analysis of conversion capacity, fatty acid composition and acyl-CoA oxidase enzyme activity. Viability of the cells was assessed by lactate dehydrogenase assay and confirmed that the cells were not negatively affected by the treatment. Both prior to seeding of cells and prior to addition of cetoleic acid, the cells were evaluated in light microscopy. The cells appeared to have a purity of close to 95% with presence of very few blood cells. Although the hepatocytes were the dominating cell type, we cannot exclude that other cell types naturally present in the liver will be a part of the hepatic cell culture. A mix of different cell types naturally existing *in vivo* will make the *in vitro* response more similar to the *in vivo* response.

Culturing of human HepG2 cells

Human HepG2 cells from three different cell batches were cultured in 25 cm² cell flasks for the following analysis: conversion capacity (four replicates), gene expression (six replicates), fatty acid composition (three replicates) and acyl-CoA oxidase enzyme activity (three replicates). The cells were cultured in DMEM with 10% FBS and incubated at 37°C and 5% CO₂. After 4 h, the cells were added experimental growth medium consisting of DMEM with 10% FBS in addition to 0, 20, 40, 60 or 80 μM cetoleic acid. The same incubation times and doses of 18 : 3*n*-3 and cetoleic acid were used for the HepG2 *in vitro* trial as in the salmon hepatocytes study. The same procedure as described for the salmon hepatocytes above was followed. Cell viability, measured by lactate dehydrogenase activity, was not negatively affected by the treatment.

Analyses fatty acid composition and fat content

Total lipids were extracted from cells, feeds, whole fish (five fish prior start of the trial and from each tank at the end) and liver samples by the method described by Folch *et al.*⁽³⁷⁾. The chloroform phase was evaporated to dryness under N₂ gas and the residual lipid re-dissolved in chloroform. Methyl esters of fatty acids were made according to a method described by Mason & Waller⁽³⁸⁾ and Hoshi *et al.*⁽³⁹⁾. The methyl esters of the fatty acids were thereafter separated in a gas chromatograph (Hewlett Packard 6890 and HP ChemStation software) with a split injector, SGE BPX70 capillary column (length 60 m, internal diameter 0.25 mm and a thickness of film of 0.25 μm) and flame

ionisation detector. Helium was used as carrier gas, and injector and detector temperatures were both 280°C. The temperature was raised from 50 to 170°C at a rate of 4°C/min, and then raised to 200°C at a rate of 0.5°C/min, and finally to 300°C at a rate of 10°C/min. The relative quantity of each fatty acid was determined by measuring the area under the peak in the GC spectrum corresponding to that fatty acid.

The radio-labelled fatty acids in the cells from the *in vitro* trials with salmon and human hepatocytes were determined by reversed-phase HPLC as described by Narce *et al.*⁽⁴⁰⁾. The mobile phase was acetonitrile–water (85:15, v/v) at a flow rate of 1 ml/min and a temperature of 30°C. The column used was a symmetry 3.5 μm C18 column (Waters) and the fatty acids were detected with a radioactive flow detector A-100 (Radiomatic Instrument & Chemicals). Identification of each fatty acid was done by comparing the sample retention times with the retention times of fatty acid standards (American Radiolabel Chemicals Inc.). The absorbance of the non-radioactive fatty acid standards (Sigma-Aldrich) was measured in a UV detector (Waters 2996 PDA Detector) at 215 nm.

Prior to incubation, aliquots of 10, 20, 40 and 50 μl of the ¹⁴C-18 : 3*n*-3 stock solution were transferred into different vials together with 5 ml of Ecoscint A scintillation liquid in order to count total radioactivity. The specific radioactivity (cpm/nmol fatty acid) was calculated for the ¹⁴C-18 : 3*n*-3 substrate. The samples were counted in a scintillation counter TRI-CARB 1900 TR (Packard Instrument Co.). The total radioactivity for all the detected fatty acids were set to 100%, and the relative distribution of each fatty acid calculated according to that.

Analysis of acyl-CoA oxidase enzyme activity

Hepatocytes (harvested from 25 cm² cell flasks) were resuspended in PBS (30 μl) and added 190 μl assay mix (0.710 ml H₂O, 0.2 ml 0.5 M Tris pH 8.5, 0.050 ml 1 mg/ml peroxidase, 0.010 ml 60 mg/ml BSA), 3 μl FAD (1.3 mg/ml), 3 μl 2.5 mg/ml in 0.01 M NaOH 2',7'-dichlorofluorescein diacetate and 3 μl 6 mg/ml PalmCoA in Tris 0.1 M buffer pH 8.5. Change in absorbance at 502 was recorded for 3 min. Activity of acyl-CoA oxidase (ACO) was defined as:

$$\text{ACO activity} = \Delta A_{502} / \text{min} / 0.156 \mu\text{M} - 1 \times 0.229 / 0.030 \\ \times \text{dilution} = \text{nmol} / \text{min} / \text{ml}.$$

Enzyme activities in both cell types were measured at room temperature (20°C), which is higher than the normal body temperature for salmon and lower than the normal body temperature for human cells. However, for both cell types, the method is established for 20°C.

Production of experimental diets for Atlantic salmon

The four diets were designed to contain either sardine oil (low in cetoleic acid) or herring oil (high in cetoleic acid) at two different inclusion levels of the oils (Low Sardine, Low Herring, High Sardine or High Herring). The cetoleic acid content within the Low and High diets therefore varied according to type of fish oil, whereas the EPA + DHA contents were balanced within



Table 1. Chemical composition of the diets (%)

| Ingredients (%) | |
|------------------------------------|-------|
| Soya protein concentrate* | 23.92 |
| Low temperature fishmeal† | 22.00 |
| Oil mix‡ | 22.00 |
| Wheat gluten§ | 13.00 |
| Wheat meal | 11.00 |
| Horse beans¶ | 3.50 |
| Monosodium phosphate** | 2.00 |
| Mineral mix** | 0.52 |
| Carophyll Pink 10 % CWS†† | 0.05 |
| Yttriumoxide‡‡ | 0.01 |
| Estimated chemical composition (%) | |
| Protein | 42.00 |
| Fat | 26.00 |

* EWOS, Norway.

† Welcon, Egersund, Norway.

‡ See Table 2 for details.

§ Tereos Syral, Belgium.

|| Norgesmøllene, Bergen, Norway.

¶ Socomac Rouen, France.

** Normin, Norway.

†† DSM, France.

‡‡ VWR, Norway.

each fish oil inclusion level with EPAX 1050 TAG oil. Ingredients and chemical composition of the basal diet were adapted to Atlantic salmon from about 100 g (Table 1). All ingredients, except for the oils, were mixed to a basal diet in which soya protein concentrate, low temperature (LT) fishmeal and wheat gluten constituted the primary source of protein. Yttrium oxide was used as marker for determining the digestibility of the nutrients. The mixture was then extruded in a Wenger TX-52 twin screw extruder to produce pellets of approximately 3 mm diameter. The pellets were dried and divided into four equal batches. Each batch was added the various oil mixtures (Table 2) using a vacuum coater. An overview of the fatty acid composition of the diets is given in Table 3 (quantitative values for fatty acid composition of the diets in Supplementary Table S1).

Feeding trial with Atlantic salmon

Atlantic salmon (101–115 g) were randomly distributed into twelve tanks, thirty fish in each tank. The fish were fed one of four feeds, three replicate tanks per feed. All tanks were equipped to collect waste feeds. An estimated excessive feeding of 20 % was practiced, and daily feed intake was recorded in order to measure feed conversion ratio (FCR). The experiment was done in saltwater (31.6 ‰) at an average temperature of 8.4°C. The initial water temperature was 8.2°C, but during the first 6 weeks, the water temperature gradually declined to 7.1°C. Heated water was used the rest of the trial period to improve feed intake and achieve the planned growth. The temperature throughout the final period was at 9.9°C. The experiment lasted 67 d to a final average fish weight of 242 g. At start and at the end of the experimental period, all experimental fish were weighed in bulk. Fish were anaesthetised in MS222 prior sampling. Whole fish were sampled for analyses of whole-body fat content and fatty acid composition (each sample consisting of a pool of five fish per tank). Liver samples for analysis of fat content and fatty

Table 2. Oil mixtures added to the diets (% of total oil added)

| | Sardine Low | Herring Low | Sardine High | Herring High |
|-------------------------------|-------------|-------------|--------------|--------------|
| Sardine oil* | 11.9 | – | 16.5 | – |
| Herring oil† | – | 48.3 | – | 66.8 |
| Rapeseed oil‡ | 80.2 | 51.7 | 72.5 | 33.2 |
| EPAX 1050 TAG (DHA-rich oil)§ | 7.9 | – | 11.0 | – |

* Emmelev, Denmark.

† Vedde, Norway.

‡ Epax AS, Norway.

§ Norsildemel, Norway.

Table 3. Fatty acid composition of the diets (% of total fatty acids)

| | Sardine Low | Herring Low | Sardine High | Herring High |
|-------------|-------------|-------------|--------------|--------------|
| 14 : 0 | 1.3 | 3.9 | 1.5 | 5.2 |
| 16 : 0 | 7.6 | 9.1 | 8.1 | 10.5 |
| 18 : 0 | 2.0 | 1.4 | 2.1 | 1.4 |
| 20 : 0 | 0.5 | 0.4 | 0.5 | 0.3 |
| Σ SFA* | 12.4 | 15.6 | 13.2 | 18.4 |
| 16 : 1n-7 | 1.5 | 2.0 | 1.6 | 2.7 |
| 18 : 1n-9 | 46.6 | 33.2 | 44.4 | 24.4 |
| 20 : 1n-11 | 0.3 | 1.4 | 0.6 | 1.9 |
| 22 : 1n-11 | 2.1 | 6.3 | 2.2 | 7.9 |
| 22 : 1n-11 | 1.5 | 10.8 | 1.3 | 14.6 |
| 24 : 1n-9 | 0.3 | 0.5 | 0.3 | 0.6 |
| Σ MUFA† | 53.1 | 56.0 | 51.2 | 53.9 |
| 20 : 4n-6 | 0.2 | 0.1 | 0.3 | 0.2 |
| 18 : 2n-6 | 16.5 | 12.8 | 15.6 | 9.7 |
| Σ n-6‡ | 17.4 | 13.5 | 16.6 | 10.6 |
| 18 : 3n-3 | 7.6 | 5.7 | 7.1 | 4.2 |
| 20 : 5n-3 | 2.9 | 2.8 | 3.9 | 3.6 |
| 22 : 5n-3 | 0.5 | 0.4 | 0.7 | 0.5 |
| 22 : 6n-3 | 4.6 | 4.4 | 5.9 | 5.5 |
| Σ n-3§ | 16.2 | 13.7 | 17.8 | 14.3 |
| Σ EPA + DHA | 7.5 | 7.2 | 9.8 | 9.1 |

* Includes 15 : 0, 17 : 0, 22 : 0, 24 : 0.

† Includes 14 : 1n-5, 16 : 1n-9, 17 : 1n-7, 18 : 1n-7, 20 : 1n-7, 22 : 1n-9, 22 : 1n-7.

‡ Includes 16 : 2n-6, 18 : 3n-6, 20 : 2n-6, 20 : 3n-6, 22 : 4n-6.

§ Includes 16 : 2n-3, 18 : 4n-3, 20 : 4n-3, 20 : 3n-3.

acid composition were sampled, quickly frozen in liquid N₂ and stored at –80°C until analysis.

Calculation of hepatosomatic index and growth parameters

Hepatosomatic index (HSI, %) was calculated as follows:

$$\text{HSI} = \text{liver weight/body weight} \times 100$$

The growth rate was calculated as both specific growth rate (SGR) and thermal growth coefficient (TGC). The following formulas were used:

$$\text{SGR} (\% \text{d}^{-1}) = (\ln W_2 - \ln W_1)(t_2 - t_1) - 1 \times 100$$

$$\text{TGC} = (W_2^{1/3} - W_1^{1/3}) / ((t_2 - t_1) \times T) - 1 \times 1000$$

where W1 and W2 are the average weight (g) at the start (t1) and end (t2) of the trial, and T is the average temperature during the period.

Table 4. Endogenous fatty acid composition (% of total fatty acids) of human HepG2 control cells and salmon control hepatocytes|| (Mean values and standard deviations, *n* 3)

| | Human HepG2 | | Salmon hepatocytes | | <i>P</i> |
|--------------------|-------------|-----|--------------------|-----|----------|
| | Mean | SD | Mean | SD | |
| 14 : 0 | 3.1 | 0.5 | 0.3 | 0.1 | 0.001 |
| 16 : 0 | 22.4 | 0.3 | 10.6 | 0.3 | <0.001 |
| 18 : 0 | 6.0 | 0.1 | 6.2 | 0.3 | 0.216 |
| ΣSFA* | 4.2 | 0.2 | 2.3 | 0.1 | 0.000 |
| 16 : 1 <i>n</i> -9 | 1.1 | 1.6 | 0.0 | 0.1 | 0.284 |
| 16 : 1 <i>n</i> -7 | 11.5 | 1.7 | 1.9 | 0.7 | 0.001 |
| 16 : 1 <i>n</i> -5 | 0.9 | 0.0 | 0.0 | 0.0 | <0.001 |
| 18 : 1 <i>n</i> -9 | 20.9 | 0.5 | 29.7 | 0.5 | <0.001 |
| 18 : 1 <i>n</i> -7 | 13.0 | 0.7 | 3.1 | 0.1 | <0.001 |
| 20 : 1 <i>n</i> -9 | 1.1 | 0.1 | 3.7 | 0.2 | <0.001 |
| ΣMUFA† | 3.5 | 0.2 | 2.7 | 0.0 | 0.003 |
| 18 : 2 <i>n</i> -6 | 1.3 | 0.1 | 3.9 | 1.7 | 0.058 |
| 20 : 2 <i>n</i> -6 | 2.0 | 0.2 | 1.5 | 0.0 | 0.004 |
| 20 : 3 <i>n</i> -6 | 0.7 | 0.0 | 1.4 | 1.1 | 0.365 |
| 20 : 4 <i>n</i> -6 | 3.5 | 0.0 | 3.6 | 0.1 | 0.179 |
| Σ <i>n</i> -6‡ | 1.6 | 0.1 | 2.1 | 0.2 | 0.023 |
| 18 : 3 <i>n</i> -3 | 0.0 | 0.0 | 0.3 | 0.3 | 0.211 |
| 20 : 3 <i>n</i> -3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.374 |
| 20 : 5 <i>n</i> -3 | 0.4 | 0.0 | 1.8 | 0.1 | 0.000 |
| 22 : 5 <i>n</i> -3 | 0.6 | 0.0 | 1.0 | 0.2 | 0.021 |
| 22 : 6 <i>n</i> -3 | 3.4 | 0.1 | 23.5 | 0.6 | <0.001 |
| Σ <i>n</i> -3§ | 0.7 | 0.0 | 3.8 | 0.1 | <0.001 |
| ΣEPA + DHA | 3.9 | 0.1 | 25.2 | 0.7 | <0.001 |

* Includes 12 : 0, 15 : 0, 17 : 0, 20 : 0, 24 : 0.

† Includes 14 : 1*n*-5, 15 : 1, 16 : 1*n*-5, 17 : 1*n*-7, 18 : 1*n*-11, 20 : 1*n*-7, 20 : 1*n*-11, 22 : 1*n*-9, 22 : 1*n*-7, 24 : 1*n*-9.

‡ Includes 18 : 3*n*-6.

§ Includes 18 : 3*n*-3, 18 : 4*n*-3, 20 : 3*n*-3.

|| Significant differences (*P* < 0.05) were ranked according to *t* test.

FCR was calculated as follows:

$$\text{FCR} = \text{weight (g) of feed eaten} / \text{growth of biomass (g)}$$

Total fat content and fatty acid composition in fish and feed, as well as feed intake and growth in each tank, were used to calculate the retention (*R*) of fatty acids in fish from each group:

$$R (\%) = (FA_2 - FA_1) / FA_s \times 100,$$

where *FA*₂ is amount of fat or fatty acid in whole fish at the end of the experimental period, *FA*₁ is amount of fat or fatty acid in whole fish at start of the trial and *FA*_s are amount of fat or fatty acids eaten during the period.

Statistics

For the *in vitro* trials, flasks were used as experimental units with three replicates for endogenous fatty acid composition and acyl-CoA oxidase enzyme activity, and four replicates for the conversion capacity of ALA to EPA and DHA. Data from the salmon feeding trial are given as mean values of three replicate units (*n* 3; three tanks per dietary group, five fish per tank to a total of fifteen fish per dietary group). All data from the *in vitro* trials, except endogenous fatty acid composition (Table 4), were subjected to one-way ANOVA, and significant differences (*P* ≤ 0.05) were ranked according to Tukey–Kramer test. Endogenous fatty acid composition in HepG2 and salmon

hepatocytes and the data from the *in vivo* trial were analysed by *t* test comparing the sardine groups with the herring groups within the Low and High groups, respectively. The software SAS 9.4 (SAS Institute Inc., 2002–2012) and Microsoft® Office Excel were used for the statistical analyses.

Results

Endogenous fatty acid composition of human HepG2 cells and salmon primary hepatocytes

Human HepG2 cells and primary hepatocytes from Atlantic salmon differed in endogenous fatty acid compositions, prior to enrichment with cetoleic acid, as shown in Table 4. The salmon hepatocytes had a 7-fold higher percentage of EPA + DHA than human HepG2 cells. The HepG2 cells, however, had higher percentages of fatty acids known to be part of the *de novo* lipogenesis, 14 : 0 and 16 : 0, and their Δ-9 desaturation and elongation products 16 : 1*n*-7 and 18 : 1*n*-7. The salmon cells had approximately 1.5 times higher percentage of 18 : 1*n*-9 and three times higher 18 : 2*n*-6 compared with human HepG2 cells. Salmon hepatocytes contained only low levels of 18 : 3*n*-3, whereas the fatty acid was not detected in HepG2 cells. When both cell types were supplemented with increasing doses from 0 to 80 μM of cetoleic acid to the culture media, the endogenous concentrations of cetoleic acid increased from 0.2 to 18.6 % (of total fatty acids) in HepG2 cells and from 0.5 to 3.7 % in salmon hepatocytes (Fig. 1).

Capacity to convert ¹⁴C-18 : 3*n*-3–¹⁴C-20 : 5*n*-3 and ¹⁴C-22 : 6*n*-3 in human HepG2 cells and salmon hepatocytes

Both HepG2 cells and salmon hepatocytes were incubated with the ¹⁴C-18 : 3*n*-3 substrate in order to study how different endogenous concentrations of cetoleic acid influence the *n*-3 metabolic pathway in the cells. There were only minor differences in total cellular nmol of radio-labelled fatty acids recovered in the different treatment groups in the two cell types after the incubation period, showing similar uptake of ¹⁴C-18 : 3*n*-3 substrate (online Supplementary Table S2). There was an increasing production of ¹⁴C-20 : 5*n*-3 and ¹⁴C-22 : 6*n*-3 from ¹⁴C-18 : 3*n*-3 in both cell types with increasing concentrations of cetoleic acid up to 40 μM in culture media, and thereafter the production levelled off or decreased (Fig. 2). Of the total radioactive products recovered in HepG2 control cells, the main fatty acids were ¹⁴C-20 : 5*n*-3 (25 %), ¹⁴C-20 : 4*n*-3 (11 %) and ¹⁴C-22 : 6*n*-3 (9 %), while in salmon control hepatocytes, the main products were ¹⁴C-22 : 6*n*-3 (17 %), ¹⁴C-20 : 5*n*-3 (16 %) and ¹⁴C-20 : 3*n*-3 (6 %) (Fig. 2 and 3, online Supplementary Table S2). While the salmon cells produced almost equal amounts of 20 : 5*n*-3 and 22 : 6*n*-3, the HepG2 cells produced approximately 3-fold more 20 : 5*n*-3 than 22 : 6*n*-3 in the control cells (Fig. 2). The high proportion of 20 : 4*n*-3 in addition to 20 : 5*n*-3 in the HepG2 indicates that the further desaturation and elongation to 22 : 6*n*-3 is more limited than in Atlantic salmon cells, where more equal amounts of 20 : 5*n*-3 and 22 : 6*n*-3 are produced (Fig. 3).

In HepG2 cells, increasing endogenous levels of cetoleic acid led to significantly higher productions of both ¹⁴C-20 : 5*n*-3,




Fig. 1. Cetoleic acid (% of total fatty acids) in HepG2 and salmon hepatocytes incubated with different doses of cetoleic acid (0–80 μM). Values are means (*n* 3), with standard errors represented by vertical bars. ^{a,b,c,d,e} Mean values for HepG2 with unlike letters were significantly different ($P \leq 0.05$, Tukey–Kramer test). ^{A,B,C,D} Mean values for salmon hepatocytes with unlike letters were significantly different ($P \leq 0.05$, Tukey–Kramer test).




Fig. 2. EPA ($^{14}\text{C}-20 : 5n-3$; ■) and DHA ($^{14}\text{C}-22 : 6n-3$; □) in HepG2 (a) and salmon hepatocytes (b) incubated with different doses of cetoleic acid (0–80 μM). Values are means (*n* 4), with standard errors represented by vertical bars. ^{a,b,c} Mean values for EPA with unlike letters were significantly different ($P \leq 0.05$, Tukey–Kramer test). ^{A,B} Mean values for DHA with unlike letters were significantly different ($P \leq 0.05$, Tukey–Kramer test).

$^{14}\text{C}-20 : 3n-3$, and $^{14}\text{C}-22 : 6n-3$, with 1.3 times more $^{14}\text{C}-20 : 5n-3$ in the cells cultured with 40 μM cetoleic acid and almost two times more $^{14}\text{C}-22 : 6n-3$ in the cells cultured with 80 μM cetoleic acid than in the control cells (Fig. 2 and 3). Probably as a result of this increased conversion to $^{14}\text{C}-20 : 5n-3$ and $^{14}\text{C}-22 : 6n-3$, the levels of $^{14}\text{C}-20 : 4n-3$, $^{14}\text{C}-22 : 5n-3$ and $^{14}\text{C}-24 : 6n-3$ were lower in HepG2 cells with cetoleic acids than in the control cells (online Supplementary Table S2). Approximately 2–4 % of the radio-labelled substrate in HepG2 cells was found as $^{14}\text{C}-20 : 3n-3$,

which is part of the alternative route to $20 : 4n-3$, by-passing $18 : 4n-3$. The level of $^{14}\text{C}-20 : 3n-3$ was up to 1.8 times higher in HepG2 cells with cetoleic acid compared with the control cells.

In salmon hepatocytes, up to 2.9 times higher level of $^{14}\text{C}-18 : 4n-3$, 1.4 times of $^{14}\text{C}-20 : 4n-3$ and 1.2 times of $^{14}\text{C}-20 : 5n-3$ were measured in cells cultured with cetoleic acid compared with the control cells (Fig. 2 and 3, online Supplementary Table S2). The synthesis of $^{14}\text{C}-22 : 6n-3$ was not different between the groups, but there was a tendency towards higher level of $^{14}\text{C}-22 : 6n-3$ in




Fig. 3. ^{14}C -20 : 3*n*-3 (■) and ^{14}C -20 : 4*n*-3 (■) in HepG2 (a) and salmon hepatocytes (b) incubated with different doses of cetoleic acid (0–80 μM). Values are means (n 4), with standard errors represented by vertical bars. ^{a,b,c} Mean values for ^{14}C -20 : 4*n*-3 with unlike letters were significantly different ($P \leq 0.05$, Tukey–Kramer test). ^{A,B} Mean values for ^{14}C -20 : 3*n*-3 with unlike letters were significantly different ($P \leq 0.05$, Tukey–Kramer test).

cells stimulated with 20 and 40 μM cetoleic acid. In salmon hepatocytes, between 4 and 6 % of the radio-labelled substrate was converted to ^{14}C -20 : 3*n*-3, involved in the alternative pathway. The control cells had the highest level of ^{14}C -20 : 3*n*-3, whereas cells added the higher doses of cetoleic acid showed 0.6–0.7 times of the level in control cells.

Compared with the salmon hepatocytes, the human cells showed a higher conversion to ^{14}C -20 : 5*n*-3; 25–33% *v.* 16–18% of total fatty acids, irrespective of endogenous level of cetoleic acid (Fig. 2). The level of ^{14}C -22 : 6*n*-3 synthesised was nearly 2-fold higher in salmon control cells compared with HepG2 control cells, but with increased endogenous level of cetoleic acid the production in HepG2 was similar to the maximal production in salmon hepatocytes, 9–17% in human hepatocytes *v.* 17–18% in salmon hepatocytes. Interestingly, this was reflected in the ratio between 20 : 5*n*-3 and 22 : 6*n*-3 which was approximately 3:1 in the HepG2s control cells and almost 2:1 in the cells cultured with cetoleic acids. In salmon hepatocytes, this ratio was close to 1:1 for all groups.

Acetyl-CoA oxidase enzyme activity in human and salmon hepatocytes

There were no significant differences in peroxisomal acetyl-CoA oxidase activity between control cells and cells cultured in cetoleic acid for both cell types (data not shown). The enzyme activity in HepG2 stimulated with 20 μM cetoleic acid was however higher than in cells stimulated with 60 and 80 μM of cetoleic acid.

In human HepG2 cells, the enzyme activities varied between 0.6 and 0.8 nmol/min per mg protein, whereas in salmon hepatocytes the enzyme activities were nearly 2-fold higher; 1.1–1.6 nmol/min per mg protein. Enzyme activities in both cell types were measured at room temperature at 20°C, indicating higher capacities in salmon liver cells than in human liver cells.

Fatty acid compositions of diets in feeding trial with Atlantic salmon

In order to study if cetoleic acid influences the *n*-3 metabolic pathway when given in the diet, Atlantic salmon were fed either sardine oil low in cetoleic acid or herring oil high in cetoleic acid at two inclusion levels (Low or High) that were balanced for EPA + DHA content. Table 3 shows the fatty acid composition of the four different diets. The two sardine oil diets contained approximately 1.4% cetoleic acid, whereas cetoleic acid accounted for 10.8 and 14.8% of total dietary fatty acids in the Low and High Herring oil diets, respectively. The EPA and DHA were approximately equally balanced with a sum of EPA + DHA of 7.5% in the Sardine Low and 7.2% in Herring Low, 9.8% in Sardine High, and 9.1% in Herring High. The SFA (mainly 16 : 0 and 14 : 0) were higher in the Herring diets (16–18%) than in the Sardine diets (13–16%). The Herring diets, however, had a lower level (1.4%) of 18:0 compared with the Sardine diets (2.0–2.1%). The *n*-6 fatty acids, mainly 18 : 2*n*-6, were 1.3 times higher in Sardine Low than in Herring Low, and 1.6 times higher in Sardine High than in Herring High.

Table 5. Growth parameters and hepatosomatic index (HSI) of salmon-fed diets based on two different levels (Low and High) of sardine or herring oil (Mean values and standard deviations, *n* 3; three tanks per dietary group, five fish per tank to a total of fifteen fish per dietary group)

| | Sardine Low | | Herring Low | | Sardine High | | Herring High | | <i>P</i> |
|----------------------------|-------------|------|-------------|------|--------------|------|--------------|------|----------|
| | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
| Weight (g) start | 109.7 | 0.2 | 108.3 | 0.7 | 111.0 | 1.9 | 110.9 | 0.6 | 0.31 |
| Weight (g) final | 240.8 | 2.0 | 240.6 | 4.5 | 240.0 | 7.6 | 247.1 | 7.3 | 0.80 |
| Specific growth rate | 1.26 | 0.01 | 1.18 | 0.03 | 1.14 | 0.05 | 1.18 | 0.05 | 0.82 |
| Thermal growth coefficient | 2.51 | 0.03 | 2.54 | 0.06 | 2.46 | 0.12 | 2.57 | 0.12 | 0.85 |
| Feed conversion ratio | 0.88 | 0.01 | 0.88 | 0.00 | 0.90 | 0.02 | 0.91 | 0.05 | 0.78 |
| HSI | 1.45 | 0.03 | 1.32 | 0.03 | 1.39 | 0.06 | 1.30 | 0.04 | 0.33 |

Table 6. Fat (%) and fatty acid composition (% of total fatty acids) in liver of salmon-fed diets based on two different levels (Low and High) of sardine or herring oil, respectively|| (Mean values and standard deviations, *n* 3; three tanks per dietary group, five fish per tank to a total of fifteen fish per dietary group)

| | Sardine Low | | Herring Low | | <i>P</i> | Sardine High | | Herring High | | <i>P</i> |
|---------------------|-------------|-----|-------------|-----|----------|--------------|-----|--------------|-----|----------|
| | Mean | SD | Mean | SD | | Mean | SD | Mean | SD | |
| Fat | 11.6 | 1.9 | 8.4 | 1.8 | 0.108 | 9.5 | 2.8 | 6.6 | 0.9 | 0.166 |
| 14 : 0 | 1.1 | 0.0 | 2.4 | 0.1 | <0.001 | 1.2 | 0.0 | 2.8 | 0.1 | <0.001 |
| 16 : 0 | 5.1 | 0.2 | 6.6 | 0.3 | 0.002 | 5.8 | 0.4 | 8.0 | 0.3 | 0.001 |
| 18 : 0 | 3.5 | 0.3 | 2.9 | 0.2 | 0.056 | 3.6 | 0.4 | 3.2 | 0.3 | 0.249 |
| ∑SFA* | 10.1 | 0.5 | 12.2 | 0.4 | 0.005 | 10.9 | 0.4 | 14.4 | 0.5 | 0.001 |
| 16 : 1 <i>n</i> -9 | 2.2 | 0.5 | 2.6 | 0.6 | 0.312 | 1.7 | 0.1 | 3.1 | 0.6 | 0.018 |
| 18 : 1 <i>n</i> -11 | 0.0 | 0.0 | 3.3 | 0.9 | 0.003 | 0.3 | 0.5 | 5.2 | 0.1 | <0.001 |
| 18 : 1 <i>n</i> -9 | 47.7 | 0.4 | 39.8 | 1.8 | 0.002 | 44.8 | 2.4 | 33.0 | 0.8 | 0.001 |
| 18 : 1 <i>n</i> -7 | 3.3 | 0.1 | 3.1 | 0.1 | 0.042 | 3.5 | 0.1 | 3.1 | 0.0 | 0.001 |
| 20 : 1 <i>n</i> -9 | 6.1 | 0.1 | 7.1 | 0.4 | 0.009 | 5.8 | 0.3 | 7.5 | 0.2 | 0.001 |
| 22 : 1 <i>n</i> -7 | 0.6 | 0.1 | 0.7 | 0.0 | 0.598 | 0.6 | 0.1 | 0.8 | 0.1 | 0.029 |
| 22 : 1 <i>n</i> -11 | 0.4 | 0.0 | 2.5 | 0.2 | 0.000 | 0.5 | 0.0 | 3.4 | 0.2 | <0.001 |
| ∑MUFA† | 61.3 | 0.8 | 60.3 | 1.1 | 0.277 | 58.2 | 2.3 | 57.3 | 1.3 | 0.598 |
| 18 : 2 <i>n</i> -6 | 12.0 | 0.4 | 9.1 | 0.3 | <0.001 | 11.4 | 0.4 | 7.3 | 0.1 | <0.001 |
| 20 : 2 <i>n</i> -6 | 2.8 | 0.1 | 2.1 | 0.1 | 0.001 | 2.6 | 0.2 | 1.6 | 0.1 | 0.001 |
| 20 : 3 <i>n</i> -6 | 0.9 | 0.0 | 0.9 | 0.1 | 0.234 | 0.8 | 0.1 | 0.6 | 0.1 | 0.013 |
| 20 : 4 <i>n</i> -6 | 0.6 | 0.1 | 0.6 | 0.1 | 0.772 | 0.8 | 0.2 | 0.6 | 0.1 | 0.275 |
| ∑ <i>n</i> -6‡ | 16.8 | 0.5 | 13.0 | 0.3 | <0.001 | 15.9 | 0.4 | 10.8 | 0.1 | <0.001 |
| 18 : 3 <i>n</i> -3 | 3.3 | 0.0 | 2.4 | 0.2 | 0.001 | 3.2 | 0.2 | 2.0 | 0.1 | 0.001 |
| 20 : 5 <i>n</i> -3 | 1.5 | 0.1 | 1.9 | 0.2 | 0.015 | 2.0 | 0.2 | 2.4 | 0.2 | 0.070 |
| 22 : 5 <i>n</i> -3 | 0.5 | 0.0 | 0.5 | 0.0 | 0.101 | 0.6 | 0.1 | 0.7 | 0.1 | 0.373 |
| 22 : 6 <i>n</i> -3 | 4.0 | 0.2 | 5.8 | 0.9 | 0.027 | 5.8 | 2.1 | 8.0 | 0.2 | 0.156 |
| ∑ <i>n</i> -3§ | 10.0 | 0.7 | 11.3 | 1.1 | 0.167 | 12.6 | 2.6 | 13.5 | 0.3 | 0.567 |
| ∑EPA + DHA | 5.5 | 0.3 | 7.7 | 1.0 | 0.024 | 7.8 | 2.3 | 10.4 | 0.3 | 0.131 |
| DHA/ALA | 1.2 | 0.1 | 2.5 | 0.5 | 0.015 | 1.8 | 0.7 | 4.1 | 0.2 | 0.007 |

* Includes 17 : 0, 20 : 0, 22 : 0.

† Includes 14 : 1*n*-5, 15 : 1, 16 : 1*n*-7, 16 : 1*n*-5, 17 : 1*n*-7, 18 : 1*n*-9T, 20 : 1*n*-11, 20 : 1*n*-7, 24 : 1*n*-9.

‡ Includes 16 : 2*n*-6, 18 : 3*n*-6.

§ Includes 18 : 4*n*-3, 20 : 4*n*-3, 20 : 3*n*-3.

|| Significant differences (*P* ≤ 0.05) were ranked according to *t* test within Low and High groups, respectively.

Growth and feed conversion ratio of salmon

The experimental fish in all dietary groups more than doubled their weight during the 2 months feeding trial from approximately 110 to approximately 240 g (Table 5). There were no differences in growth rate between the four dietary groups with specific growth rate of 1.15–1.18 and thermal growth coefficient of 2.46–2.57. The FCR was between 0.88 and 0.91 and there were no differences between the dietary groups. There was low mortality in the trial; only one dead fish was registered.

Hepatosomatic index, fat percentage and fatty acid composition of salmon liver

There was a tendency towards lower level of liver fat (%) in the Herring Low compared with Sardine Low (8.4 *v.* 11.6%), and in

Herring High compared with Sardine High (6.6 *v.* 9.5%) (Table 5).

There were no significant differences in HSI between the dietary groups, but numerically lower HSI in the groups fed a diet containing herring oil (HSI at 1.3) *v.* the groups fed the corresponding diet containing sardine oil (HSI at 1.4–1.5) (Table 5). The level of cetoleic acid (%) in the liver reflected the fatty acid composition of the diets with 6–7 times higher level in the Herring groups compared with their corresponding Sardine groups (Table 6; quantitative levels of fatty acids in liver are shown in online Supplementary Table S3). There was no difference in the level of cetoleic acid between the Sardine groups, but the Herring High group had approximately 1.4 times higher level than the Herring Low group.

The level of EPA was significantly higher in the Herring Low compared with the Sardine Low group (1.9 *v.* 1.5%), and almost in the Herring High compared with the Sardine High group

Table 7. Whole-body fat level (%) and fatty acid composition (% of total fatty acids) of salmon-fed diets based on two different levels (Low and High) of sardine or herring oil, respectively|| (Mean values and standard deviations, *n* 3; three tanks per dietary group, five fish per tank to a total of fifteen fish per dietary group)

| | Sardine Low | | Herring Low | | <i>P</i> | Sardine High | | Herring High | | <i>P</i> |
|---------------------|-------------|-----|-------------|-----|----------|--------------|-----|--------------|-----|----------|
| | Mean | SD | Mean | SD | | Mean | SD | Mean | SD | |
| Fat | 15.2 | 0.5 | 15.1 | 0.1 | 0.925 | 15.0 | 0.8 | 14.9 | 0.4 | 0.752 |
| 14 : 0 | 2.1 | 0.1 | 3.3 | 0.0 | <0.001 | 2.1 | 0.0 | 4.0 | 0.1 | <0.001 |
| 16 : 0 | 10.1 | 0.1 | 10.7 | 0.1 | 0.001 | 10.2 | 0.4 | 11.4 | 0.2 | 0.010 |
| 18 : 0 | 2.5 | 0.1 | 2.2 | 0.1 | 0.007 | 2.8 | 0.4 | 2.2 | 0.1 | 0.042 |
| ∑SFA* | 15.5 | 0.1 | 17.0 | 0.1 | <0.001 | 16.0 | 0.7 | 18.4 | 0.3 | 0.006 |
| 16 : 1 <i>n</i> -7 | 2.0 | 0.0 | 2.6 | 0.1 | 0.003 | 2.3 | 0.2 | 2.9 | 0.2 | 0.014 |
| 18 : 1 <i>n</i> -9 | 36.6 | 0.5 | 30.9 | 0.2 | <0.001 | 34.8 | 0.5 | 26.0 | 0.4 | <0.001 |
| 20 : 1 <i>n</i> -11 | 1.1 | 0.0 | 1.3 | 0.0 | 0.001 | 1.0 | 0.1 | 1.3 | 0.0 | 0.001 |
| 20 : 1 <i>n</i> -9 | 4.1 | 0.1 | 6.1 | 0.0 | <0.001 | 4.1 | 0.1 | 6.9 | 0.0 | <0.001 |
| 22 : 1 <i>n</i> -7 | 0.7 | 0.0 | 0.9 | 0.0 | 0.002 | 0.6 | 0.2 | 1.0 | 0.0 | 0.025 |
| 22 : 1 <i>n</i> -11 | 2.7 | 0.2 | 7.0 | 0.1 | <0.001 | 2.7 | 0.2 | 8.8 | 0.2 | <0.001 |
| 24 : 1 <i>n</i> -9 | 0.4 | 0.2 | 0.6 | 0.0 | 0.083 | 0.4 | 0.1 | 0.6 | 0.0 | 0.005 |
| ∑MUFA† | 48.3 | 0.1 | 49.8 | 0.2 | <0.001 | 46.7 | 0.4 | 48.3 | 0.2 | 0.004 |
| 18 : 2 <i>n</i> -6 | 12.4 | 0.1 | 10.5 | 0.0 | <0.001 | 11.9 | 0.1 | 9.0 | 0.2 | <0.001 |
| 20 : 2 <i>n</i> -6 | 1.2 | 0.0 | 1.0 | 0.0 | <0.001 | 1.1 | 0.1 | 0.9 | 0.0 | 0.010 |
| ∑ <i>n</i> -6‡ | 15.2 | 0.1 | 13.0 | 0.1 | <0.001 | 14.5 | 0.2 | 11.4 | 0.1 | <0.001 |
| 18 : 3 <i>n</i> -3 | 4.4 | 0.0 | 3.6 | 0.0 | <0.001 | 4.4 | 0.1 | 3.2 | 0.1 | <0.001 |
| 20 : 5 <i>n</i> -3 | 2.5 | 0.1 | 2.6 | 0.1 | 0.102 | 2.7 | 0.1 | 3.1 | 0.2 | 0.062 |
| 22 : 5 <i>n</i> -3 | 0.9 | 0.0 | 0.9 | 0.0 | 0.970 | 1.0 | 0.0 | 1.1 | 0.1 | 0.153 |
| 22 : 6 <i>n</i> -3 | 7.8 | 0.1 | 7.7 | 0.1 | 0.472 | 8.4 | 0.2 | 8.6 | 0.1 | 0.334 |
| ∑EPA/DHA | 10.3 | 0.1 | 10.4 | 0.1 | 0.381 | 11.1 | 0.3 | 11.6 | 0.1 | 0.069 |
| ∑ <i>n</i> -3§ | 11.8 | 0.1 | 11.7 | 0.0 | 0.229 | 12.9 | 0.4 | 13.2 | 0.0 | 0.210 |
| DHA/ALA | 1.8 | 0.0 | 2.1 | 0.0 | <0.001 | 1.9 | 0.1 | 2.7 | 0.1 | <0.001 |

* Includes 20 : 0.

† Includes 20 : 1*n*-7.

‡ Includes 18 : 3*n*-6, 20 : 3*n*-6, 20 : 4*n*-6, 22 : 4*n*-6.

§ Includes 20 : 4*n*-3, 20 : 3*n*-3.

|| Significant differences ($P \leq 0.05$) were ranked according to *t* test within Low and High groups, respectively.

(2.4 *v.* 2.0%, $P=0.070$). Herring Low also showed significantly higher level of DHA compared with Sardine Low (4.0 *v.* 5.8%); however, there was no significant difference between the two High groups. The sum of EPA + DHA was more than 1.3 times higher in the Herring High group (10%) than in the other groups (6–8%). The DHA to ALA ratio may be considered as an indicator of bioconversion capacity from ALA to DHA in the liver, and this ratio was approximately 2-fold higher in the Herring groups compared with in their corresponding Sardine groups.

Interestingly, although not available in any of the diets, 18 : 1*n*-11 accounted for 3 and 5% of total fatty acids in the Low and High Herring groups, respectively. The level of 18 : 1*n*-11 was close to 0% in the livers of the Sardine groups.

The total SFA and total *n*-6 fatty acids more or less reflected the dietary composition with a higher level of total SFA in the Herring groups and higher level of *n*-6 fatty acids in the Sardine groups.

Fat content, fatty acid composition and retention in whole body of salmon

There were no differences in total fat content of whole body between the dietary groups. The EPA content was nearly significantly higher ($P=0.06$) in whole body of the Herring High group than in the Sardine High group (3.1 *v.* 2.7%), whereas the EPA level in the Herring Low group was not different from that in the Sardine Low group (Table 7; quantitative levels of fatty acids in whole body are shown in online Supplementary Table S4). There were no significant differences in the level

of DHA or total *n*-3 fatty acids between the Sardine Low and the Herring Low groups, or between the Sardine High and the Herring High groups. Despite of a lower dietary DHA content in the Herring groups compared with those in the corresponding Sardine groups, equal or even higher DHA percentages were observed in the whole body from salmon receiving the Herring diets. Both Herring groups had significantly higher levels of SFA than the Sardine groups, 17.0–18.4 *v.* 15.5–16.0%. The fatty acids 18 : 0, 16 : 0 and 14 : 0 were the main contributors to the measured level of SFA, reflecting the composition of these fatty acids in the diet. The Sardine groups had significantly higher levels of total *n*-6 fatty acids than the Herring groups (1.2–1.3 times higher), with 18 : 2*n*-6 being the most prominent fatty acid. The level of cetoleic acid reflected the composition of the diet, with approximately three times higher levels in the Herring groups compared with the Sardine groups, and Herring High with the highest level (1.3 times higher than Herring Low). The liver level of cetoleic acid (in mg/g) was approximately 2 times higher for the Herring groups and almost 1.3 times higher for the Sardine groups than in the whole body. The main contributor to the MUFA level, 18 : 1*n*-9, was significantly higher in the Sardine groups (37% in the High and 35% in the Low groups) compared with the Herring groups (26% in the High and 31% in the Low groups). The ratio DHA to ALA was significantly higher for both Herring groups than in the comparable Sardine groups, indicating increased synthesis capacity of the *n*-3 pathway in these groups.

Whole-body apparent retention of EPA, 22 : 5*n*-3, and EPA + DHA was significantly higher in fish fed the highest

Table 8. Retention of fat and fatty acids (%) in whole body of salmon-fed diets based on two different levels (Low and High) of sardine or herring oil, respectively* (Mean values and standard deviations, *n* 3; three tanks per dietary group, five fish per tank to a total of fifteen fish per dietary group)

| | Sardine Low | | Herring Low | | <i>P</i> | Sardine high | | Herring high | | <i>P</i> |
|---------------------|-------------|------|-------------|------|----------|--------------|------|--------------|------|----------|
| | Mean | SD | Mean | SD | | Mean | SD | Mean | SD | |
| Fat | 75.5 | 4.7 | 74.2 | 0.5 | 0.644 | 70.2 | 5.5 | 72.5 | 3.9 | 0.654 |
| 14 : 0 | 81.5 | 5.6 | 63.7 | 1.5 | 0.006 | 64.0 | 7.9 | 60.9 | 3.9 | 0.650 |
| 16 : 0 | 96.1 | 6.2 | 86.7 | 1.7 | 0.065 | 86.0 | 12.3 | 82.4 | 3.7 | 0.731 |
| 18 : 0 | 98.9 | 8.9 | 106.9 | 6.9 | 0.292 | 104.9 | 26.7 | 110.0 | 1.0 | 0.815 |
| 20 : 0 | 50.3 | 2.9 | 52.9 | 0.2 | 0.189 | 58.3 | 15.4 | 57.9 | 2.2 | 0.978 |
| ∑SFA | 87.0 | 5.4 | 79.4 | 1.5 | 0.078 | 80.3 | 13.2 | 75.7 | 3.2 | 0.674 |
| 18 : 1 <i>n</i> -9 | 67.1 | 4.4 | 73.2 | 0.9 | 0.080 | 61.6 | 4.7 | 75.9 | 3.6 | 0.036 |
| 20 : 1 <i>n</i> -11 | 181.9 | 5.5 | 59.9 | 1.8 | <0.001 | 80.5 | 8.0 | 47.1 | 5.5 | 0.015 |
| 20 : 1 <i>n</i> -9 | 113.4 | 7.6 | 72.4 | 1.4 | 0.001 | 100.6 | 16.6 | 68.1 | 4.3 | 0.082 |
| 22 : 1 <i>n</i> -11 | 55.2 | 4.4 | 53.2 | 1.6 | 0.495 | 49.6 | 25.4 | 52.2 | 5.1 | 0.899 |
| ∑MUFA | 70.0 | 4.1 | 68.9 | 0.9 | 0.688 | 64.2 | 5.6 | 67.2 | 4.0 | 0.578 |
| 18 : 2 <i>n</i> -6 | 64.4 | 3.5 | 64.4 | 0.5 | 0.988 | 60.2 | 3.2 | 67.1 | 2.0 | 0.080 |
| 20 : 4 <i>n</i> -6 | 113.0 | 10.9 | 120.6 | 10.1 | 0.422 | 91.4 | 19.5 | 79.3 | 13.1 | 0.505 |
| ∑ <i>n</i> -6 | 73.5 | 4.1 | 74.0 | 0.6 | 0.838 | 67.3 | 2.9 | 75.8 | 3.2 | 0.054 |
| 18 : 3 <i>n</i> -3 | 50.5 | 2.6 | 50.2 | 0.5 | 0.852 | 49.9 | 1.3 | 55.5 | 0.4 | 0.012 |
| 20 : 5 <i>n</i> -3 | 51.6 | 2.6 | 58.3 | 3.5 | 0.059 | 41.8 | 1.9 | 60.7 | 3.9 | 0.005 |
| 22 : 5 <i>n</i> -3 | 101.2 | 6.7 | 133.2 | 8.5 | 0.007 | 90.8 | 10.4 | 145.3 | 21.8 | 0.029 |
| 22 : 6 <i>n</i> -3 | 107.6 | 7.4 | 109.5 | 2.3 | 0.684 | 88.8 | 5.6 | 101.0 | 6.8 | 0.114 |
| ∑ <i>n</i> -3 | 87.9 | 5.3 | 90.4 | 0.3 | 0.449 | 75.3 | 4.0 | 85.8 | 5.9 | 0.095 |
| ∑EPA + DHA | 85.7 | 5.2 | 89.3 | 1.0 | 0.300 | 70.2 | 4.0 | 85.0 | 5.6 | 0.040 |

* Significant differences ($P \leq 0.05$) were ranked according to *t* test within Low and High groups, respectively.

dietary content of herring oil compared with sardine oil (Table 8, Fig. 4). The Herring High group had approximately 15 % points higher retention of EPA + DHA compared with Sardine High. There was also significantly higher retention of 22 : 5*n*-3 and nearly significantly higher retention of EPA ($P=0.059$) in Herring Low compared with Sardine Low. The retention of cetoleic acid was not different between the dietary groups.

Discussion

In the present study, we demonstrate for the first time that cetoleic acid, either provided from herring oil in the diet of Atlantic salmon or as supplementation in pure form to growth media of human and salmon cell models, resulted in higher capacities of all experimental systems to convert ALA to EPA and DHA. Interesting species-specific differences were revealed when comparing human HepG2 cells with salmon hepatocytes. Although DHA is known to inhibit the *n*-3 metabolic pathway^(27–29) and the salmon cells had almost 10-fold higher endogenous level of DHA than the human HepG2 cells, more radio-labelled DHA was produced from ALA in salmon cells than in HepG2 cells. Also, a higher ratio of EPA to DHA of 3 : 1 in human HepG2 cells compared with a more equal ratio (1:1) in salmon hepatocytes indicates a more restricted further desaturation and elongation from EPA to DHA in HepG2 cells than in salmon hepatocytes, implying that the last steps in bioconversion from EPA to DHA is a limiting step in the *n*-3 metabolic pathway in the human cells. This is in agreement with previous findings showing that increased dietary intake of ALA in humans, led to increased EPA content in plasma phospholipid, but not increased DHA, indicating a limited capacity for DHA production from EPA⁽³³⁾.

The reason for the higher capacity to produce DHA even at relatively high endogenous levels of DHA in salmon cells, was

recently discussed in a study by Bou *et al.*⁽³⁶⁾, and may be due to elongation of ALA to 20 : 3*n*-3 via elongase 5, and thereby bypassing the $\Delta 6$ desaturase step of the pathway converting ALA to 18 : 3*n*-4 (which is inhibited by DHA). Previously, 20 : 3*n*-3 was considered as a dead-end product of the LC-PUFA synthesis pathway. However, both in mammals and teleosts, there is an alternative $\Delta 8$ pathway for the synthesis of LC-PUFA^(41–43). By the $\Delta 8$ desaturase activity, 20 : 3*n*-3 is converted to 20 : 4*n*-3, a precursor for EPA. This pathway represents an alternative route to synthesise EPA independently of $\Delta 6$ desaturase activity. The regulatory mechanisms for neither elongation or desaturation of ALA, nor for the $\Delta 8$ desaturase activity, are known. The cellular DHA content, however, seems to have a major effect modulating the activity of the pathway by regulating the conversion of ALA to either 20 : 3*n*-3 or 18 : 4*n*-3⁽³⁶⁾. Salmon hepatocytes with high cellular level of DHA had enhanced the production of 20 : 3*n*-3^(36,44–46).

However, stimulation of the cells with cetoleic acid in our study demonstrates a potential to improve the conversion capacity from ALA to DHA in HepG2 cells, since cetoleic acid reduced the ratio EPA:DHA from 3:1 to 2:1 and increased 2-fold the production of DHA compared with control cells. At increasing dietary doses of cetoleic acid, the ratio of 20 : 3*n*-3 to 20 : 4*n*-3 was also reduced, maybe indicating that this bypass route gets more important with cetoleic acid in the diet and thereby one possible factor explaining the increased DHA production in HepG2 cells enriched with cetoleic acid.

Although the cell line HepG2 has maintained a functional *n*-3 fatty acid metabolic pathway⁽⁴⁷⁾, it still may differ to some extent in metabolic properties from primary human hepatocytes⁽⁴⁸⁾. In order to fully determine the effects of cetoleic acid in humans, studies with primary human liver cells reflecting the functional performance of the organ *in vivo* are required in future studies. However, it is a strength that the overall effects of cetoleic acid on




Fig. 4. Retention of EPA, docosapentaenoic acid and DHA in Atlantic salmon-fed diets based on two different levels (Low and High) of sardine or herring oil, respectively. Values are means (*n*3; three tanks per dietary group), with standard deviations represented by vertical bars. * Significant difference between sardine and herring groups (*P* ≤ 0.05, *t* test).

the *n*-3 metabolic pathway in HepG2 is similar to the response in salmon primary liver cells, even if there are some species differences.

The higher production of DHA in salmon cells relative to HepG2 cells, even though they contained a much higher DHA level, may not only be due to bypassing the Δ6 desaturase step to 20 : 3*n*-3 that is shuffled back into the pathway alone, but also due to a higher peroxisomal β-oxidation capacity in these cells. Peroxisomal β-oxidation is involved in the last step of the *n*-3 metabolic pathway shortening 24 : 6*n*-3 to DHA. LC-PUFA, including DHA, are known to stimulate the capacity of the peroxisomal β-oxidation pathway⁽⁴⁹⁾, which may explain the higher conversion from EPA to DHA in salmon cells than in HepG2 cells. The activity of acyl CoA-oxidase, the first enzyme in peroxisomal β-oxidation pathway, in salmon cells was nearly 2-fold higher than in HepG-2 cells. This may indicate a higher peroxisomal activity in salmon cells compared with human cells. It is known that carnivore coldwater fish species in general have high peroxisomal β-oxidation capacity due to their adapted to a diet rich in LC-PUFA⁽⁵⁰⁾. However, cetoleic acid did not influence the activity of acyl CoA-oxidase in any of the cell types contrary to one of the hypotheses of the present study. Previous studies with rodents fed a diet based on MUFA reported an increased EPA level and a slightly induced peroxisomal β-oxidation, in liver^(11,12,51). Opstvedt⁽⁵⁾ hypothesised that LC-MUFA would lead to increased peroxisomal β-oxidation and thereby increased synthesis of *n*-3 LC PUFA. Even though the measured activity of acyl co-A oxidase was not different for the HepG2 and salmon hepatocytes cultured in different doses of cetoleic acid, addition of cetoleic acid increased the synthesis of ¹⁴C-22 : 6*n*-3 in human hepatocytes, indicating a higher peroxisomal conversion of 24 : 6*n*-3 to DHA. However, we have only measured the first enzyme in the peroxisomal β-oxidation pathway. In order to verify the higher capacity of the pathway, the peroxisomal β-oxidations end products need to be determined in future studies.

Other studies have also shown that the LC-PUFA synthesis pathway can be stimulated by different bioactive compounds like the MUFA petroselinic acid^(14,36). Trout hepatocytes exposed to petroselinic acid increased the elongation and desaturation of ¹⁴C-18 : 3*n*-3 to DHA, possibly through stimulated peroxisomal

β-oxidation capacity (with more acetate produced, a product of the pathway)⁽¹⁴⁾. Thus, cetoleic acid might be having a similar effect in HepG2 cells and salmon hepatocytes in this experiment.

In our study, a salmon feeding trial was put up to investigate if dietary cetoleic acid, provided in herring oil, would have the same effects *in vivo* as those observed in the *in vitro* cell trials. The finding of higher apparent retentions in whole body of EPA, 22 : 5*n*-3, and EPA + DHA in the Herring High group compared with the Sardine High group, as well as of EPA and 22 : 5*n*-3 in Herring Low compared with Sardine Low, indicated that the level of cetoleic acid in the dietary herring oil indeed led to higher metabolic conversion of dietary ALA to EPA and 22 : 5*n*-3. The retention of 22 : 5*n*-3 in the Herring groups at 130–145 % and more than 1.3–1.6 times higher than in the Sardine groups further supports the assumption of increased *n*-3 metabolic pathway in the Herring dietary groups due to their cetoleic acid content. The higher retention of EPA and DHA may also be influenced by the low retention of 22 : 1*n*-11 pointing to the high utilisation of this fatty acid as an energy source, which may spare LC-PUFA from β-oxidation. Despite the lower EPA + DHA level in the Herring High feed compared with the Sardine High feed (9.1 *v.* 9.8 % of total fatty acids), there was nearly significantly higher level of EPA (*P* = 0.062) in whole-body mass of the Herring High than in Sardine High. Further, the DHA to ALA ratio, indicating increased synthesis capacity, was significantly higher in the Herring groups than in the Sardine groups. This supports the hypothesis that the cetoleic acid content of herring oil stimulates the salmon's capacity to synthesise EPA and DHA from dietary ALA. In the *in vivo* trial, the peroxisomal β-oxidation capacity was not measured and can therefore not be used to explain the salmon results. In earlier studies with rodents, diets high in LC-MUFA and low in PUFA also resulted in increased levels of EPA and DHA levels in both plasma and liver^(7,8,12,52), although the mechanisms for this effect was not shown. Nevertheless, earlier feeding trials with rats have shown that diets based on marine oils (capelin) or rapeseed oil, that are rich in the LC-MUFA (like the 22 : 1 fatty acids), caused increased peroxisomal β-oxidation^(53,54).

The fatty acid composition of the livers from fish in the feeding trial further supported the findings from the *in vitro* trials and

whole-body fatty acid data. In the liver, the percentage of EPA and DHA was significantly higher in the Herring Low group compared with the Sardine Low, and the level of EPA was nearly significantly higher in the Herring High than in the Sardine High. Both relative and quantitative values showed significantly increased, or a trend towards increased, DHA in the liver of the Herring groups compared with the Sardine groups, even when the Herring groups had approximately 30% lower fat content than the Sardine groups. In addition, the DHA:ALA ratio in the Herring groups more than doubled when compared with the Sardine groups, indicating a higher conversion of dietary ALA to DHA in the livers of the Herring High groups, since the dietary level of DHA was similar. Although not significant, there was a strong tendency to reduced fat percentage in the livers in the Herring group compared with Sardine groups, which may indicate that cetoleic acid leads to reduced fat accumulation in the liver. Erucic acid (22 : 1n-9) has previously been linked to cardiac lipodosis in rats fed diets containing rapeseed oil high in this fatty acid⁽⁵⁵⁾. This has however not been reported for cetoleic acid. Further, mice fed a diet enriched in saury oil high in MUFA showed increased levels of n-11 MUFA in plasma and organs, suppressed genes related to adipogenesis and induced genes involved in fatty acid oxidation^(6,56). Herring oil is rich in MUFA, which have been reported to stimulate peroxisomal β -oxidation^(11,12,57). The higher endogenous EPA level in the Herring High group may also explain the differences in liver fat content between the different groups. In previous studies, EPA was shown to inhibit lipid secretion from salmon hepatocytes, however, increased the mitochondrial area and proliferation, indicating stimulatory effect on mitochondrial β -oxidation^(58,59). Reduction of liver fat content was also observed in mice fed a diet rich in LC-MUFA⁽⁶⁰⁾. This was explained by down-regulation of hepatic genes involved in cholesterol and lipid synthesis.

Interestingly, there was a significant difference in the level of cetoleic acid in whole-body *v.* in liver. The content of cetoleic acid in the liver in mg/g tissue was approximately 2 times higher than in the whole body of the Herring groups and more than 1.2–1.3 times higher for the Sardine groups. This may indicate that cetoleic acid is deposited to a higher degree in the liver than in muscle. Further, the liver profile showed accumulation of 18 : 1n-11 in the Herring groups, whereas almost nothing was identified in the Sardine groups. This fatty acid is not found in the diets and is probably a chain-shortening product of cetoleic acid. Accumulation of this fatty acid was also seen in organs and carcasses of rats fed cetoleic acid⁽⁶¹⁾, but the impact of the fatty acid is unknown. This shows the potential for health beneficiary effects of aquaculture salmon rich in cetoleic acid for human consumption.

Conclusion

In conclusion, cell trials showed that cetoleic acid stimulates the synthesis of EPA and DHA in human HepG2 and of EPA in salmon hepatocytes. Further, feeding Atlantic salmon a herring oil-based diet rich in cetoleic acid increased hepatic content of EPA and DHA and whole-body retention of EPA, docosapentaenoic acid and EPA + DHA. The results show that cetoleic acid, in

addition to EPA and DHA, contributes to the health beneficiary effects of fish oils both in human diets, and as dietary ingredients for the aquaculture industry.

Acknowledgements

We would like to acknowledge Inger Øien Kristiansen, Målfrid Bjerke and Silje Kristine Bergum for excellent work in the laboratory.

This work was supported by The Norwegian Seafood Research Fund (FHF) – project number FHF901017.

T.-K. K. Ø., B. R., G. M. B. and O. H. R. designed the study, T.-K. K. Ø., M. B. and G. M. B. performed the analyses, T.-K. K. Ø. and B. R. wrote the manuscript, T.-K. K. Ø., B. R., G. M. B., M. B., A. N. and O. H. R. reviewed and edited the manuscript.

The authors declare that there are no conflicts of interest.

Supplementary material

For supplementary material/s referred to in this article, please visit <https://doi.org/10.1017/S0007114519001478>

References

1. Turchini GM, Ng W-K & Tocher DR (2010) *Fish Oil Replacement and Alternative Lipid Sources in Aquaculture Feeds*. Boca Raton, FL: CRC Press.
2. Calder PC (2014) Very long chain omega-3 (n-3) fatty acids and human health. *Eur J Lipid Sci Tech* **116**, 1280–1300.
3. Bou M, Berge GM, Baeverfjord G, *et al.* (2017) Requirements of n-3 very long-chain PUFA in Atlantic salmon (*Salmo salar* L): effects of different dietary levels of EPA and DHA on fish performance and tissue composition and integrity. *Br J Nutr* **117**, 30–47.
4. Bou M, Berge GM, Baeverfjord G, *et al.* (2017) Low levels of very-long-chain n-3 PUFA in Atlantic salmon (*Salmo salar*) diet reduce fish robustness under challenging conditions in sea cages. *J Nutr Sci* **6**, e32.
5. Opstvedt J (1997) Fish lipids: more than n-3 fatty acids? *Med Hypotheses* **48**, 481–483.
6. Yang ZH, Miyahara H, Takemura S, *et al.* (2011) Dietary saury oil reduces hyperglycemia and hyperlipidemia in diabetic KKAY mice and in diet-induced obese C57BL/6J mice by altering gene expression. *Lipids* **46**, 425–434.
7. Yang ZH, Miyahara H, Iwasaki Y, *et al.* (2013) Dietary supplementation with long-chain monounsaturated fatty acids attenuates obesity-related metabolic dysfunction and increases expression of PPAR gamma in adipose tissue in type 2 diabetic KK-Ay mice. *Nutr Metab* **10**, 16.
8. Yang ZH, Bando M, Sakurai T, *et al.* (2016) Long-chain monounsaturated fatty acid-rich fish oil attenuates the development of atherosclerosis in mouse models. *Mol Nutr Food Res* **60**, 2208–2218.
9. Stubhaug I, Lie Ø & Torstensen B (2007) Fatty acid productive value and β -oxidation capacity in Atlantic salmon (*Salmo salar* L.) fed on different lipid sources along the whole growth period. *Aquacult Nutr* **13**, 145–155.
10. Sargent JR, Tocher DR & Bell JG (2002) The lipids. *Fish Nutr* **3**, 181–257.



11. Bremer J & Norum KR (1982) Metabolism of very long-chain monounsaturated fatty acids (22 : 1) and the adaptation to their presence in the diet. *J Lipid Res* **23**, 243–256.
12. Halvorsen B, Rustan AC, Madsen L, *et al.* (2001) Effects of long-chain monounsaturated and *n*-3 fatty acids on fatty acid oxidation and lipid composition in rats. *Ann Nutr Metab* **45**, 30–37.
13. Sprecher H (2000) Metabolism of highly unsaturated *n*-3 and *n*-6 fatty acids. *Biochim Biophys Acta Mol Cell Biol Lipids* **1486**, 219–231.
14. Randall KM, Drew MD, Overland M, *et al.* (2013) Effects of dietary supplementation of coriander oil, in canola oil diets, on the metabolism of [1-(14C) 18:3*n*-3 and [1-(14C) 18:2*n*-6 in rainbow trout hepatocytes. *Comp Biochem Physiol B Biochem Mol Biol* **166**, 65–72.
15. Berge GM, Østbye T-KK, Kjær MA, *et al.* (2015) *Betydning av genetisk bakgrunn og ulike nivå av n-3-fettsyrer i før i tidlig livsfaser for fiskebelse, fettysammensetning og muskelkvalitet ved slaktestørrelse. FHF-prosjekt 900770–delrapport 2. (Meaning of Genetic Background and Different Levels of n-3 Fatty Acids in Early Feeding Life Stages for Fish Health, Fatty Acid Composition and Muscle Quality at Slaughter Size. FHF Project 900770 – Interim Report 2).* Tromsø: Nofima.
16. Østbye T-KK, Berge GM, Sonesson AK, *et al.* (2015) *Kan forlenget opphold i ferskvann, før overføring til saltvann, påvirke laksens kapasitet til å omdanne 18 : 3 n-3 til EPA og DHA? FHF-prosjekt 900770–delrapport 3 (Can Prolonged Residence in Fresh Water, Prior to Transfer to Saline, Affect Salmon's Capacity to Convert 18 : 3n-3 to EPA and DHA? FHF Project 900770 – Interim Report 3).* Tromsø: Nofima AS.
17. Ruyter B, Østbye T-KK, Kjær MA, *et al.* (2015) *Kan nivå av EPA og DHA i før i tidlige livsfaser påvirke laksens belse og sammensetning i seinere livsfaser? FHF-prosjekt 900770–Delrapport 1 (Can Level of EPA and DHA in Feed in Early Life Stages Affect Salmon's Health and Composition in Later Life Stages? FHF project 900770 – Interim report 1).* Tromsø: Nofima AS.
18. Torstensen BE, Bell JG & Rosenlund G *et al.* (2005) Tailoring of Atlantic salmon (*Salmo salar* L.) flesh lipid composition and sensory quality by replacing fish oil with a vegetable oil blend. *J Agric Food Chem* **53**, 10166–10178.
19. Bell JG, Henderson RJ, Tocher DR, *et al.* (2002) Substituting fish oil with crude palm oil in the diet of Atlantic salmon (*Salmo salar*) affects muscle fatty acid composition and hepatic fatty acid metabolism. *J Nutr* **132**, 222–230.
20. Rosenlund G, Obach A, Sandberg M, *et al.* (2001) Effect of alternative lipid sources on long-term growth performance and quality of Atlantic salmon (*Salmo salar* L.). *Aquac Res* **32**, 323–328.
21. Burdge GC, Jones AE & Wootton SA (2002) Eicosapentaenoic and docosapentaenoic acids are the principal products of alpha-linolenic acid metabolism in young men. *Br J Nutr* **88**, 355–363.
22. Burdge GC & Wootton SA (2002) Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. *Br J Nutr* **88**, 411–420.
23. Postle AD, Al MD, Burdge GC, *et al.* (1995) The composition of individual molecular species of plasma phosphatidylcholine in human pregnancy. *Early Hum Dev* **43**, 47–58.
24. Zhang JY, Kothapalli KS & Brenna JT (2016) Desaturase and elongase limiting endogenous long chain polyunsaturated fatty acid biosynthesis. *Curr Opin Clin Nutr Metab Care* **19**, 103.
25. Hastings N, Agaba MK, Tocher DR, *et al.* (2004) Molecular cloning and functional characterization of fatty acyl desaturase and elongase cDNAs involved in the production of eicosapentaenoic and docosahexaenoic acids from alpha-linolenic acid in Atlantic salmon (*Salmo salar*). *Mar Biotechnol* **6**, 463–474.
26. Monroig Ó, Zheng X, Morais S, *et al.* (2010) Multiple genes for functional Δ6 fatty acyl desaturases (Fad) in Atlantic salmon (*Salmo salar* L.): gene and cDNA characterization, functional expression, tissue distribution and nutritional regulation. *Biochim Biophys Acta Mol Cell Biol Lipids* **1801**, 1072–1081.
27. Thomassen MS, Rein D, Berge GM, *et al.* (2012) High dietary EPA does not inhibit Δ5 and Δ6 desaturases in Atlantic salmon (*Salmo salar* L.) fed rapeseed oil diets. *Aquaculture* **360**, 78–85.
28. Pawlosky RJ, Hibbeln JR, Lin Y, *et al.* (2003) Effects of beef-and fish-based diets on the kinetics of *n*-3 fatty acid metabolism in human subjects. *Am J Clin Nutr* **77**, 565–572.
29. Emken E, Adlof R, Duval S, *et al.* (1999) Effect of dietary docosahexaenoic acid on desaturation and uptake in vivo of isotope-labeled oleic, linoleic, and linolenic acids by male subjects. *Lipids* **34**, 785–791.
30. Ruyter B & Thomassen MS (1999) Metabolism of *n*-3 and *n*-6 fatty acids in Atlantic salmon liver: stimulation by essential fatty acid deficiency. *Lipids* **34**, 1167–1176.
31. Burdge GC, Tan S-Y & Henry CJ (2017) Long-chain *n*-3 PUFA in vegetarian women: a metabolic perspective. *J Nutr Sci* **6**, e58.
32. Salem N & Kuratko CN (2011) Lack of evidence for increased alpha-linolenic acid metabolism in vegetarians. *Am J Clin Nutr* **93**, 1154–1155.
33. Burdge GC & Calder PC (2005) Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. *Reprod Nutr Dev* **45**, 581–597.
34. Shepherd CJ, Monroig O & Tocher DR (2017) Future availability of raw materials for salmon feeds and supply chain implications: the case of Scottish farmed salmon. *Aquaculture* **467**, 49–62.
35. Dannevig BH & Berg T (1985) Endocytosis of galactose-terminated glycoproteins by isolated liver cells of the rainbow trout (*Salmo gairdneri*). *Comp Biochem Physiol B Biochem Mol Biol* **82**, 683–688.
36. Bou M, Østbye T-K, Berge GM, *et al.* (2017) EPA, DHA, and lipoic acid differentially modulate the *n*-3 fatty acid biosynthetic pathway in Atlantic salmon hepatocytes. *Lipids* **52**, 265–283.
37. Folch J, Lees M & Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. *J Biol Chem* **226**, 497–509.
38. Mason M & Waller G (1964) Dimethoxypropane induced transesterification of fats and oils in preparation of methyl esters for gas chromatographic analysis. *Anal Chem* **36**, 583–586.
39. Hoshi M, Williams M & Kishimoto Y (1973) Esterification of fatty acids at room temperature by chloroform–methanolic HCl–cupric acetate. *J Lipid Res* **14**, 599–601.
40. Narce M, Gresti J & Bezard J (1988) Method for evaluating the bioconversion of radioactive polyunsaturated fatty acids by use of reversed-phase liquid chromatography. *J Chromatogr* **448**, 249–264.
41. Monroig O, Li Y & Tocher DR (2011) Delta-8 desaturation activity varies among fatty acyl desaturases of teleost fish: high activity in delta-6 desaturases of marine species. *Comp Biochem Physiol B Biochem Mol Biol* **159**, 206–213.
42. Park WJ, Kothapalli KS, Lawrence P, *et al.* (2009) An alternate pathway to long-chain polyunsaturates: the FADS2 gene product Δ8-desaturates 20: 2*n*-6 and 20: 3*n*-3. *J Lipid Res* **50**, 1195–1202.
43. Stroud CK, Nara TY, Roqueta-Rivera M, *et al.* (2009) Disruption of FADS2 gene in mice impairs male reproduction and causes dermal and intestinal ulceration. *J Lipid Res* **50**, 1870–1880.
44. Ruyter B, Rosjo C, Einen O, *et al.* (2000) Essential fatty acids in Atlantic salmon: time course of changes in fatty acid composition of liver, blood and carcass induced by a diet deficient in *n*-3 and *n*-6 fatty acids. *Aquacult Nutr* **6**, 109–117.

45. Vestergren ALS, Trattner S, Mráz J, *et al.* (2011) Fatty acids and gene expression responses to bioactive compounds in Atlantic salmon (*Salmo salar* L.) hepatocytes. *Neuro Endocrinol Lett* **32**, 41–50.
46. Stubhaug I, Tocher DR, Bell JG *et al.* (2005) Fatty acid metabolism in Atlantic salmon (*Salmo salar* L.) hepatocytes and influence of dietary vegetable oil. *Comp Biochem Physiol B Biochem Mol Biol* **1734**, 277–288.
47. Wu MT, Su HM, Cui Y, *et al.* (2015) Fucoxanthin enhances chain elongation and desaturation of alpha-linolenic acid in HepG2 cells. *Lipids* **50**, 945–953.
48. Zeilinger K, Freyer N, Damm G, *et al.* (2016) Cell sources for in vitro human liver cell culture models. *Exp Biol Med* **241**, 1684–1698.
49. Willumsen N, Hexeberg S, Skorve J, *et al.* (1993) Docosahexaenoic acid shows no triglyceride-lowering effects but increases the peroxisomal fatty acid oxidation in liver of rats. *J Lipid Res* **34**, 13–22.
50. Moyes CD & Crockett EL (1994) Peroxisomes and peroxisomal β -oxidation. In *Biochemistry and Molecular Biology of Fishes*, vol. 3, pp. 503–512 [PW Hochachka and TP Mommsen, editors]. New York: Elsevier.
51. Halvorsen B, Rustan AC & Christiansen EN (1995) Effect of long-chain mono-unsaturated and *n*-3 polyunsaturated fatty acids on postprandial blood and liver lipids in rats. *Scand J Clin Lab Invest* **55**, 469–475.
52. Yang Z-H, Miyahara H, Mori T, *et al.* (2011) Beneficial effects of dietary fish-oil-derived monounsaturated fatty acids on metabolic syndrome risk factors and insulin resistance in mice. *J Agric Food Chem* **59**, 7482–7489.
53. Neat CE, Thomassen MS & Osmundsen H (1980) Induction of peroxisomal β -oxidation in rat liver by high-fat diets. *Biochem J* **186**, 369–371.
54. Neat C, Thomassen M & Osmundsen H (1981) Effects of high-fat diets on hepatic fatty acid oxidation in the rat. Isolation of rat liver peroxisomes by vertical-rotor centrifugation by using a self-generated, iso-osmotic, Percoll gradient. *Biochem J* **196**, 149–159.
55. Beare-Rogers J (1977) Docosenoic acids in dietary fats. *Prog Chem Fats Other Lipids* **15**, 29–56.
56. Yang ZH, Inoue S, Taniguchi Y, *et al.* (2015) Long-term dietary supplementation with saury oil attenuates metabolic abnormalities in mice fed a high-fat diet: combined beneficial effect of *n*-3 fatty acids and long-chain monounsaturated fatty acids. *Lipids Health Dis* **14**, 155.
57. Flatmark T & Christiansen E (1993) *Modulation of Peroxisomal Biogenesis and Lipid Metabolizing Enzymes by Dietary Factors*, vol. 5. London: Taylor & Francis.
58. Vegusdal A, Gjøen T, Berge R, *et al.* (2005) Effect of 18: 1n-9, 20: 5n-3, and 22: 6n-3 on lipid accumulation and secretion by Atlantic salmon hepatocytes. *Lipids* **40**, 477–486.
59. Kjær M, Vegusdal A, Gjøen T, *et al.* (2008) Effect of rapeseed oil and dietary *n*-3 fatty acids on triacylglycerol synthesis and secretion in Atlantic salmon hepatocytes. *Biochim Biophys Acta Mol Cell Biol Lipids* **1781**, 112–122.
60. Yang Z-H, Miyahara H, Takeo J, *et al.* (2011) Pollock oil supplementation modulates hyperlipidemia and ameliorates hepatic steatosis in mice fed a high-fat diet. *Lipids Health Dis* **10**, 189.
61. Craig B & Beare JL (1967) The β -oxidative degradation of docosenoic acids to eicosenoic and octadecenoic acids in the rat. *Can J Biochem* **45**, 1075–1079.